The health and developmental status of very low-birth-weight children at school age

M C McCormick1, J Brooks-Gunn, K Workman-Daniels

  • 1Department of Maternal and Child Health, Harvard School of Public Health, Boston, Mass 02115.

JAMA
|April 22, 1992
PubMed

Insights

Children born at lower birth weights face more health issues at school age. Early intervention programs are crucial for improving outcomes for premature infants and reducing long-term health problems.

Area of Science:

  • Pediatrics
  • Neonatology
  • Developmental Pediatrics

Background:

  • Improved survival rates for premature infants necessitate understanding their long-term health outcomes.
  • Assessing school-age outcomes provides critical insights into the effects of prematurity and low birth weight.

Purpose of the Study:

  • To evaluate the school-age health status of children born at various birth weights, focusing on the impact of increasing survival rates of premature infants.
  • To identify specific health morbidities and developmental outcomes associated with different birth weight categories.

Main Methods:

  • Inception cohort study design.
  • Inclusion of very low-birth-weight (<= 1500g) infants and a stratified random sample of heavier birth-weight children.
  • Follow-up at 8-10 years using interviews and home/clinic visits for 65.1% of eligible participants.

Main Results:

  • Decreasing birth weight correlated with increased morbidity across most measures, excluding affective health.
  • Infants with birth weights <= 1500g had a higher likelihood of experiencing multiple health problems.
  • Maternal education influenced IQ outcomes for children >1000g, with socioeconomic disadvantage negatively impacting all children regardless of birth weight.

Conclusions:

  • Lower birth weight is associated with increased morbidity during early school years.
  • Post-discharge and early intervention programs are vital for mitigating risks and improving long-term health for vulnerable children.
  • Understanding these long-term outcomes emphasizes the need for continued support and monitoring of children born at low birth weights.
Abstract

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...